Consistently, panepoxydone inhibits NFkB and FOXM1 and exhibits a strong anti-tumor activity against breast cancer cell lines including ER+/HER2− MCF7 cells [52], underlining the relevance of NFkB and FOXM1 as targets in ER+/HER2− breast cancer. This evidence concerns the gene ERBB2 and neoplasm.